Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Production of Egrifta is of major material news.

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Oct 30, 2024 11:27am

39 Views

Post# 36288788

RE:RE:Production of Egrifta is of major material news.

Yes, this is obviously material. Good or bad they need to disclose.

Trogarzon wrote: Probably... they can't even share a basic information about if yes or no a batch of Egrifta was made on Oct 21. I think it's material and borderline withholding information from shareholders if so.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland